QC
TENX icon

Quadrature Capital’s Tenax Therapeutics TENX Stock Holding History

Quadrature Capital’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$247K Sell
15,472
-5,176
-25% -$70K ﹤0.01% 1048
2025
Q4 		$252K Buy
+20,648
New +$180K ﹤0.01% 904

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Quadrature Capital's TENX Position: Q1 2026 in Review

Quadrature Capital reduced its Tenax Therapeutics (TENX) stake by 25% in Q1 2026, selling an estimated $70K and leaving 15,472 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #1048.

Quadrature Capital first reported a position in TENX in Q4 2025 and has held it in 2 quarters since. The position peaked at $252K in Q4 2025. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Quadrature Capital held 15,472 shares of Tenax Therapeutics worth $247K as of Q1 2026.
  • Quadrature Capital sold 5,176 Tenax Therapeutics shares in Q1 2026, an estimated $70K.
  • Tenax Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1048 holding.
  • Quadrature Capital first reported a position in Tenax Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Tenax Therapeutics position peaked at $252K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.